Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego
- Sensus Healthcare presenting advancements in superficial radiotherapy at ASTRO Annual Meeting
- Devices offer non-surgical, painless, and cosmetically appealing treatment option
- None.
BOCA RATON, Fla, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces its participation in the American Society for Radiation Oncology (ASTRO) Annual Meeting to be held in San Diego from October 1-4. Leveraging this esteemed event, Sensus Healthcare is set to present its full line of state-of-the-art superficial radiotherapy (SRT) devices for the treatment of non-melanoma skin cancer and keloids to hospital administrators and radiation oncologists from around the world.
ASTRO is the premier gathering of radiation oncology professionals, where industry leaders converge to discuss breakthrough technologies and cutting-edge treatment methodologies. As a pioneer in the field of non-invasive, non-pharmaceutical oncology treatment, Sensus Healthcare is excited to showcase its advancements in superficial radiotherapy at this prestigious event, while demonstrating its SRT-100™, SRT-100+™, SRT-100 Vision™ with IG-SRT, using the latest ultrasound technology for accurate visualization of the dermis and Sentinel™, its proprietary IT Solutions product.
Sensus Healthcare's devices utilize the Multi-Dimensional Superficial Radiotherapy platform, which provides an alternative low-energy X-ray treatment for various types of non-melanoma skin cancer and keloids. Designed to deliver effective and safe radiotherapy, SRT offers patients a non-surgical, painless and cosmetically appealing treatment option. By enabling seamless integration with existing healthcare systems, Sensus Healthcare's solutions ensure enhanced flexibility and convenience for healthcare providers.
With the goal of improving patient quality of life, Sensus Healthcare prides itself on offering innovative, patient-centric solutions. ASTRO 2023 provides an exceptional opportunity for attendees to explore the capabilities of Sensus' advanced technologies and engage with company representatives. Participants will gain valuable insights into Sensus' unparalleled product portfolio, which boast minimal side effects and industry-leading clinical outcomes.
"We are delighted to be part of ASTRO 2023 and are excited to connect with radiation oncologists and healthcare providers from across the globe," said Joe Sardano, CEO of Sensus Healthcare. "Our groundbreaking SRT devices have revolutionized the treatment of non-melanoma skin cancers and keloids, offering patients highly effective, non-invasive options. We are eager to share our technological advancements and collaborate with industry experts to enhance patient care within radiation oncology."
ASTRO 2023 participants are invited to visit Sensus Healthcare at Booth 2553 in the San Diego Convention Center to witness live product demonstrations and interact with the company's knowledgeable representatives. To schedule an appointment or for more information about Sensus Healthcare's participation, please contact Sensus Healthcare by visiting www.sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2023; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
To date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have not had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
